Augmentation of host resistance to microbial infections by recombinant human interleukin-1 alpha.
Recombinant human interleukin-1 alpha augmented resistance of mice to microbial infections caused by Pseudomonas aeruginosa, Klebsiella pneumoniae, Staphylococcus aureus, Streptococcus pneumoniae, Salmonella typhimurium, and Candida albicans. The effective doses of interleukin-1 alpha ranged from 0.01 to 10 micrograms per mouse, depending on the infecting organism, route of administration, and challenge dose. Intravenous interleukin-1 alpha was, dose for dose, more effective than intravenous muramyl dipeptide and lentinan against the P. aeruginosa and K. pneumoniae infections. Augmentation by interleukin-1 alpha of resistance to infection was also observed in P. aeruginosa-infected mice in a state of cyclophosphamide-induced leucopenia. Interleukin-1 alpha may be useful for controlling obstinate infections not curable by antimicrobial agents alone.
Minami
A
A
Research Laboratories, Dainippon Pharmaceutical Co., Ltd., Osaka, Japan.
Fujimoto
K
K
Ozaki
Y
Y
Nakamura
S
S
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000627:therapeutic use; D000818:Animals; D003141:Communicable Diseases / Q000628:therapy*; D004305:Dose-Response Relationship, Drug; D007113:Immunity, Innate; D007167:Immunotherapy; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D007375:Interleukin-1 / Q000008:administration & dosage / Q000627:therapeutic use*; D007710:Klebsiella Infections / Q000628:therapy; D007912:Lentinan / Q000627:therapeutic use; D007970:Leukopenia / Q000503:physiopathology; D051379:Mice; D011552:Pseudomonas Infections / Q000628:therapy; D011994:Recombinant Proteins
D007375:Interleukin-1; D011994:Recombinant Proteins; D007912:Lentinan; D000119:Acetylmuramyl-Alanyl-Isoglutamine